The NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) pathway is a master regulator of immune response, inflammation, and cell survival. However, when dysregulated, it becomes a driving force behind various malignancies, including Hodgkin lymphoma, where it promotes unchecked cellular proliferation and impedes programmed cell death, or apoptosis. The challenge has been to selectively target components of this pathway without causing widespread immune suppression or off-target effects. IKKβ (IκB kinase beta) stands out as a linchpin in this process, mediating phosphorylation of inhibitors that otherwise restrain NF-κB activity.

The research team orchestrated a sophisticated approach to selectively inhibit IKKβ through SIKB-7543, a small molecule designed to fit precisely within the enzyme’s active site. This high-affinity interaction effectively dampens the kinase’s capacity to activate the NF-κB pathway. By doing so, the cascade of aberrant signals responsible for sustaining lymphoma cell survival is interrupted, leading to marked reductions in cellular proliferation coupled with the activation of apoptotic mechanisms.

Crucial to this breakthrough is the molecule’s unique chemical structure, which enables it to distinguish IKKβ from other kinases, thereby minimizing unintended consequences on related signaling pathways. The 11,11’-methylenebisdibenzo[a, c]phenazine scaffold confers exceptional binding specificity and stability, underscoring the importance of rational drug design rooted in structural biology. Such specificity holds the potential to reduce toxicity and enhance therapeutic indices in clinical settings, a perennial hurdle in cancer treatment.

Extensive in vitro analysis demonstrated that SIKB-7543 potently suppresses the proliferation of Hodgkin lymphoma cell lines. The compound induced pronounced apoptotic responses, as evidenced by hallmark cellular markers including caspase activation and DNA fragmentation. These effects were directly linked to the attenuation of NF-κB signaling, corroborating the inferred mechanism of action. Importantly, normal lymphoid cells exhibited relative resistance to SIKB-7543’s cytotoxic effects, underscoring the selective targeting mechanism.

The implications of NF-κB modulation extend beyond inhibiting tumor growth; by reactivating apoptosis, this strategy addresses a fundamental cancer hallmark—evading programmed cell death. It also suggests that SIKB-7543 may overcome resistance mechanisms that have historically limited the efficacy of conventional chemotherapies. As lymphoma cells rely heavily on continuous NF-κB signaling for survival under therapeutic stress, disrupting this axis could sensitize tumors to existing treatments.

Further biochemical characterization revealed that SIKB-7543 effectively impairs IKKβ kinase activity by stabilizing it in an inactive conformation. This conformational locking prevents phosphorylation processes essential for NF-κB activation, thereby halting downstream transcriptional programs responsible for tumor proliferation and immune evasion. This insight opens avenues for combination therapies, wherein SIKB-7543 could be paired with immunomodulatory agents to amplify anti-lymphoma effects.

The discovery emerged from an integration of computational molecular docking studies and empirical validation assays. Initial in silico screening identified 11,11’-methylenebisdibenzo[a, c]phenazine as a promising candidate due to its favorable binding affinity and physicochemical properties. Subsequent cellular assays and kinase activity measurements reinforced computational predictions, exemplifying the synergy between modern drug discovery methodologies.

This exciting development resonates strongly within the oncology research community, given the persistent challenge of treating Hodgkin lymphoma, especially in relapsed or refractory cases. While existing therapies have markedly improved survival rates, resistance and relapse remain problematic. The ability to selectively disarm critical signaling hubs like IKKβ represents a promising frontier to exploit vulnerabilities in lymphoma cell biology.

Looking ahead, preclinical studies involving animal models are anticipated to evaluate the pharmacokinetics, biodistribution, and safety profiles of SIKB-7543. Establishing the translational viability of this compound is essential before advancing into clinical trials. The selectivity and efficacy witnessed in cell culture models offer hope for a therapeutic agent with potent anti-lymphoma activity while sparing normal tissues.

Beyond Hodgkin lymphoma, the aberrant activation of NF-κB is implicated in a spectrum of cancers and inflammatory diseases. Thus, the therapeutic potential of IKKβ-specific inhibitors like SIKB-7543 might extend across multiple pathological conditions characterized by chronic NF-κB activation. This broad applicability underscores the wider impact of this research on personalized medicine and targeted drug development.

With the rise of precision oncology, tailoring treatments to the unique molecular signatures of tumors has become paramount. This study exemplifies the paradigm, harnessing an intricate understanding of signaling networks to devise molecularly targeted interventions. The nuanced modulation of IKKβ by SIKB-7543 epitomizes the future of cancer therapy, where efficacy is maximized and collateral damage minimized.

In conclusion, the selective inhibition of IKKβ by 11,11’-methylenebisdibenzo[a, c]phenazine heralds a new chapter in the treatment of Hodgkin lymphoma. By effectively downregulating aberrant NF-κB signaling, this strategy disrupts the malignant equilibrium that sustains tumor growth and survival. The compelling evidence supporting SIKB-7543’s mechanism and therapeutic potential positions it as a strong candidate for further development and clinical application.

As cancer therapy continues to evolve towards precise molecular targeting, discoveries such as this demonstrate the power of combining chemical innovation with deep biological insight. The promise of SIKB-7543 rests not only in its ability to combat lymphoma but also in paving the way for a new class of kinase inhibitors that could transform oncological therapeutics on a global scale.

This research marks a significant milestone in oncology, offering renewed hope for patients battling Hodgkin lymphoma and reaffirming the critical importance of targeting intracellular signaling pathways in cancer. The journey from molecular discovery to clinical impact may be complex, but the potential rewards—improved survival, reduced toxicity, and enhanced quality of life—are profound and inspiring.

Subject of Research: Targeting IKKβ to modulate NF-κB signaling in Hodgkin lymphoma.

Article Title: Selectively targeting the IKKβ by 11,11’-methylenebisdibenzo[a, c]phenazine (SIKB-7543) downregulates aberrant NF-κB signaling to control the proliferation and induce apoptosis in Hodgkin lymphoma.

Article References: Abohassan, M., Al Shahrani, M.M., AlOuda, S.K. et al. Selectively targeting the IKKβ by 11,11’-methylenebisdibenzo[a, c]phenazine (SIKB-7543) downregulates aberrant NF-κB signaling to control the proliferation and induce apoptosis in Hodgkin lymphoma. Med Oncol 42, 519 (2025). https://doi.org/10.1007/s12032-025-03073-w

Image Credits: AI Generated

The study, published on May 29 in the journal Redox Biology, is spearheaded by doctoral candidate Austin C. MacMillan and senior investigator Tom Cunningham, PhD, whose laboratory focuses on deciphering the complex biochemical pathways driven by oncogenes. MYC, often described as a master regulator, revs up the metabolic machinery of cancer cells, fueling their explosive growth. However, despite extensive knowledge about the individual pathways influenced by MYC, the precise orchestration and coordination of these metabolic networks have remained elusive, particularly their role in manipulating the redox state of lymphoma cells.

At the heart of redox biology lies the delicate equilibrium between oxidative and reductive processes—an essential balance for cell function and survival. Cells maintain this balance through a tightly regulated exchange of electrons, akin to a cellular battery cycling between charged and discharged states. An oxidative state reflects electron loss, while a reductive state reflects electron gain. Cancer cells, under the influence of MYC, manipulate this redox balance to prevent oxidative damage and sustain unchecked proliferation. Disrupting this homeostasis offers a promising avenue to selectively weaken or kill cancer cells without harming normal tissue.

The research team focused on a pivotal enzyme complex known as phosphoribosyl pyrophosphate synthetase (PRPS), which exists in two isoforms in lymphoma cells: PRPS1 and PRPS2. These enzymes regulate the synthesis of phosphoribosyl pyrophosphate (PRPP), a key metabolite for nucleotide biosynthesis and other crucial cellular functions. Utilizing cutting-edge CRISPR-Cas9 gene-editing technology, the researchers selectively knocked out each isoform in lymphoma cell models, enabling them to delineate the distinct and overlapping roles of PRPS1 and PRPS2 in regulating cellular metabolism and redox balance.

The experiments revealed that while both PRPS1 and PRPS2 are vital to lymphoma pathophysiology, they perform differential yet collaborative roles within a biochemical complex profoundly impacting cellular redox homeostasis. Notably, PRPS2 expression and activity were significantly upregulated in lymphoma cells with MYC overexpression, suggesting that MYC co-opts this enzyme complex to remodel metabolic fluxes for its oncogenic agenda. This remodeling alters redox buffering capacity, helping cancer cells to tolerate oxidative stress inflicted by their rapid growth and hostile microenvironment.

Dr. MacMillan elaborates on the surprising discovery that modulation of a single enzymatic step by PRPS can induce widespread alterations in cellular redox states. “We typically expect metabolic networks to exhibit substantial redundancy and buffering capacity, making it rare for one enzymatic activity to exert such global influence.” Yet, the team observed that disrupting PRPS1 heightened cellular sensitivity to oxidative stress, culminating in increased damage within lymphoma cells, whereas abrogation of PRPS2 led to a paradoxical shift toward reductive stress—an accumulation of reducing equivalents that can itself be cytotoxic.

Understanding this dualistic role is pivotal because it demonstrates that MYC-driven lymphoma cells rely on a finely tuned PRPS complex to maintain redox equilibrium, which is essential for their survival. Targeting this enzymatic hub holds therapeutic promise. By strategically inhibiting PRPS enzymes, researchers envision pushing lymphoma cells beyond their narrow window of redox tolerance, selectively triggering cell death or sensitizing tumors to existing chemotherapies and novel oxidative stress-inducing agents.

Professor Cunningham highlights the translational potential of these insights: “The interplay between MYC and the PRPS complex offers a unique metabolic vulnerability. Therapeutic strategies that disrupt this interface have the potential to destabilize cancer cell metabolism profoundly.” The team is currently developing molecular tools and small molecule inhibitors to manipulate PRPS activity with precision. Such agents could be integrated into combination therapy regimens aimed at eradicating resistant and aggressive lymphomas characterized by MYC overexpression.

Another intriguing aspect of the study is the identification of PRPS2 loss as one of the rare few genetic manipulations capable of inducing reductive stress. This phenomenon occurs when excessive reducing agents accumulate, perturbing cellular function and leading to a distinct form of stress that can be therapeutically exploited. Because cancer metabolism is notoriously adaptable, having multiple strategies to tip the redox balance abnormally equips researchers with a broader arsenal against lymphoma.

Through preclinical screening, the lab plans to identify additional compounds and molecular pathways that synergize with PRPS inhibition to further destabilize lymphoma cells’ redox systems. These efforts aim to create a new generation of targeted therapies that go beyond broad cytotoxic approaches, minimizing collateral damage and improving patient outcomes. The integration of metabolic and redox biology thus holds promise for highly selective cancer therapeutics.

The publication also clarifies conflict of interest statements: MacMillan and Cunningham have filed a patent application related to this research, underscoring the innovative translational potential of their findings. Other authors involved in the study declared no competing interests. The collaborative team includes Bibek Karki, Juechen Yang, Karmela Gertz, Samantha Zumwalde, Jay Patel, Maria Czyzyk-Krzeska, and Jarek Meller.

Given the critical role of MYC in diverse cancers, the implications of tuning PRPS-mediated redox homeostasis transcend lymphoma and may inspire broader oncological research. The study exemplifies how unraveling metabolic interdependencies can reveal hidden vulnerabilities, providing a conceptual blueprint for next-generation cancer therapies that exploit the bioenergetic and redox peculiarities of tumor cells.

As lymphoma remains a significant clinical challenge with often limited treatment options for aggressive forms, this research represents hope for patients and clinicians alike. By harnessing insights into redox biology and metabolic control, the scientific community advances closer to therapies that not only inhibit cancer growth but do so with precision and adaptability, reducing the burden of side effects and overcoming resistance.

This landmark study highlights the power of combining innovative genetic tools, rigorous biochemical analysis, and an integrative understanding of cancer metabolism. It stands at the forefront of an evolving landscape where cancer treatment transitions from broad-spectrum cytotoxicity to exquisitely targeted metabolic intervention, setting a new paradigm in oncology research.

Subject of Research:
Metabolic regulation and redox homeostasis in MYC-driven lymphoma mediated by phosphoribosyl pyrophosphate synthetase (PRPS) enzyme complex.

Article Title:
PRPS activity tunes redox homeostasis in Myc-driven lymphoma

News Publication Date:
29-May-2025

Web References:
https://doi.org/10.1016/j.redox.2025.103649

Image Credits:
Photo: University of Cincinnati

Keywords:
Lymphoma, Cancer metabolism, Redox homeostasis, MYC oncogene, PRPS1, PRPS2, CRISPR gene editing, Phosphoribosyl pyrophosphate synthetase, Oxidative stress, Reductive stress, Cancer therapeutics, Metabolic vulnerabilities

Diffuse large B-cell lymphoma is notoriously challenging due to its rapid progression and resistance to conventional therapies. Targeting cellular vulnerabilities such as ferroptosis—a type of programmed cell death driven by iron-dependent lipid peroxidation—has emerged as a novel strategy. Previous attempts to induce ferroptosis faced obstacles in efficiently translating these mechanisms into clinical treatment, which underscores the importance of identifying molecular regulators like PRDX1.

PRDX1 serves critical cellular functions in maintaining redox homeostasis by detoxifying peroxides, thereby protecting cells against oxidative stress. Its role in cancer biology remains complex, often exhibiting dual characteristics; while it can protect normal cells by mitigating oxidative damage, it also aids cancer cell survival under stressful microenvironmental conditions. The current study provides compelling evidence that PRDX1 is upregulated in DLBCL—suggesting it acts as a cancer promoter by shielding malignant cells from ferroptotic death.

Utilizing a combination of bioinformatics and quantitative real-time PCR, the researchers quantified elevated PRDX1 expression in DLBCL tissues and cell lines relative to healthy counterparts. This overexpression correlates with enhanced proliferative and invasive capabilities, highlighting PRDX1’s potential as a therapeutic target. Subsequent in vitro experiments demonstrated that silencing PRDX1 expression adversely affects lymphoma cell viability by restricting proliferation, inhibiting migration and invasion, and promoting apoptotic pathways.

The authors then explored the interplay between PRDX1 and ferroptosis, using erastin, a small molecule known to induce ferroptosis specifically. Upon PRDX1 knockdown, lymphoma cells exhibited heightened sensitivity to erastin, evidenced by increased intracellular iron and malondialdehyde (MDA) levels—hallmarks of lipid peroxidation. Moreover, a concomitant decrease in glutathione (GSH) levels was observed, further corroborating the intensified ferroptotic process. This biochemical milieu not only amplifies ferroptosis but simultaneously suppresses vital protective proteins such as GPX4 and SLC7A11, which typically inhibit ferroptotic cell death.

A deeper mechanistic analysis uncovered that PRDX1 modulates the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway, a crucial signaling cascade involved in cellular growth, differentiation, and survival. The study revealed that PRDX1 knockdown decreased the phosphorylation of MEK and ERK kinases, effectively dampening MAPK/ERK pathway activity. Such inhibition corresponds with diminished malignancy of DLBCL cells and enhanced ferroptosis.

Importantly, the role of MAPK/ERK signaling in this context was further validated using anisomycin, an agonist of the pathway. Treatment with anisomycin reversed the suppressive effects on proliferation and invasion induced by PRDX1 silencing, and concurrently mitigated the enhancement of ferroptosis. These findings pinpoint the MAPK/ERK pathway as a downstream effector mediating the oncogenic impact of PRDX1 in DLBCL, providing a targetable link between redox regulation and malignancy.

The in vivo relevance of these observations was substantiated through xenograft tumor models, where PRDX1 knockdown markedly suppressed tumor growth in mice. This compelling evidence positions PRDX1 as an indispensable promoter of DLBCL progression and a regulator of ferroptotic susceptibility. By destabilizing the balance between cellular antioxidants and iron-dependent oxidative damage, PRDX1 knockdown primes lymphoma cells for ferroptosis, thus opening avenues for combinatorial therapeutic approaches integrating ferroptosis inducers.

This study’s implications extend beyond DLBCL. The elucidated connection between PRDX1, ferroptosis, and the MAPK/ERK pathway may be relevant across various malignancies where oxidative stress and MAPK signaling are aberrant. Targeting such multifaceted mechanisms offers heightened specificity and efficacy, potentially overcoming resistance seen with monotherapies.

From a clinical perspective, PRDX1 emerges as a promising biomarker for disease aggressiveness and therapeutic responsiveness. Measuring PRDX1 levels could aid in stratifying patients most likely to benefit from ferroptosis-based treatments. Moreover, suppression of PRDX1 activity might synergize with existing chemotherapeutic and immunotherapeutic modalities to enhance outcomes.

The intersection of ferroptosis and oncogenic signaling illuminated in this investigation heralds a paradigm shift. Instead of solely focusing on inhibiting cancer growth, harnessing regulated cell death pathways like ferroptosis, in conjunction with modulating survival signals such as MAPK/ERK, presents a dual-hit strategy against resilient tumors. This approach is poised to revolutionize targeted cancer therapy, particularly for aggressive lymphomas lacking effective treatment options.

In summary, this landmark research deciphers how PRDX1 orchestrates the survival and ferroptotic vulnerability of DLBCL cells through MAPK/ERK pathway regulation. Reducing PRDX1 levels sensitizes lymphoma cells to ferroptosis induction by erastin, impairs tumorigenic behaviors, and halts disease progression in preclinical models. As the scientific community continues to unravel the complexities of redox biology in cancer, such insights pave the way for novel, efficacious therapeutics tailored to exploit tumor-specific metabolic vulnerabilities.

The prospect of integrating PRDX1-targeted strategies with ferroptosis-inducing agents and MAPK pathway modulators offers exciting translational potential. Future research will undoubtedly explore combination regimens, dosing schedules, and delivery mechanisms to optimize patient outcomes while minimizing off-target effects. Ultimately, this study exemplifies the power of molecular oncology in identifying weaknesses within cancer’s armor and transforming them into therapeutic triumphs.

Subject of Research: Diffuse large B-cell lymphoma (DLBCL) and the role of peroxiredoxin 1 (PRDX1) in ferroptosis and MAPK/ERK pathway regulation.

Article Title: PRDX1 knockdown promotes erastin-induced ferroptosis and impedes diffuse large B-cell lymphoma development by inhibiting the MAPK/ERK pathway.

Article References:
Lin, C., Xie, S., Wang, M. et al. PRDX1 knockdown promotes erastin-induced ferroptosis and impedes diffuse large B-cell lymphoma development by inhibiting the MAPK/ERK pathway.
BMC Cancer 25, 806 (2025). https://doi.org/10.1186/s12885-025-14173-1

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14173-1